LU91682I2 - Adenuric - febuxostat - Google Patents

Adenuric - febuxostat

Info

Publication number
LU91682I2
LU91682I2 LU91682C LU91682C LU91682I2 LU 91682 I2 LU91682 I2 LU 91682I2 LU 91682 C LU91682 C LU 91682C LU 91682 C LU91682 C LU 91682C LU 91682 I2 LU91682 I2 LU 91682I2
Authority
LU
Luxembourg
Prior art keywords
polymorphs
present
producing
provides
isobutyloxyphenyl
Prior art date
Application number
LU91682C
Other languages
English (en)
Other versions
LU91682I9 (fr
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15953825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91682(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of LU91682I2 publication Critical patent/LU91682I2/fr
Publication of LU91682I9 publication Critical patent/LU91682I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU91682C 1998-06-19 2010-04-22 Adenuric - febuxostat LU91682I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17307998 1998-06-19
PCT/JP1999/003258 WO1999065885A1 (fr) 1998-06-19 1999-06-18 Modifications polymorphes de 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-acide carboxylique et procedes de preparation associes

Publications (2)

Publication Number Publication Date
LU91682I2 true LU91682I2 (fr) 2010-06-22
LU91682I9 LU91682I9 (fr) 2019-01-09

Family

ID=15953825

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91682C LU91682I2 (fr) 1998-06-19 2010-04-22 Adenuric - febuxostat

Country Status (38)

Country Link
US (1) US6225474B1 (fr)
EP (4) EP1020454B2 (fr)
JP (1) JP3547707B2 (fr)
KR (1) KR100511183B1 (fr)
CN (3) CN102020617B (fr)
AT (2) ATE522512T2 (fr)
AU (1) AU748026B2 (fr)
BE (1) BE2010C024I2 (fr)
BG (1) BG64734B1 (fr)
BR (1) BR9906539A (fr)
CA (2) CA2301863C (fr)
CY (3) CY1109720T1 (fr)
CZ (1) CZ298170B6 (fr)
DE (2) DE69941672D1 (fr)
DK (3) DK1956014T3 (fr)
ES (3) ES2336287T5 (fr)
FR (1) FR10C0022I2 (fr)
GT (1) GT199900216A (fr)
HR (2) HRP20120217B1 (fr)
HU (2) HU229405B1 (fr)
ID (1) ID25775A (fr)
IL (1) IL134594A (fr)
IN (1) IN191537B (fr)
IS (4) IS9020A (fr)
LT (1) LT1956014T (fr)
LU (1) LU91682I2 (fr)
NO (1) NO321308B1 (fr)
NZ (1) NZ503326A (fr)
PL (1) PL200710B1 (fr)
PT (3) PT1956014T (fr)
RU (1) RU2198169C3 (fr)
SI (3) SI1956015T2 (fr)
SK (2) SK287928B6 (fr)
TR (1) TR200000458T1 (fr)
TW (1) TWI248439B (fr)
UA (1) UA57611C2 (fr)
WO (1) WO1999065885A1 (fr)
ZA (1) ZA200000737B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU748026B2 (en) 1998-06-19 2002-05-30 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)- 4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
WO2003006441A1 (fr) * 2001-07-10 2003-01-23 Pharmacia & Upjohn Company Cristaux a base de thiazine oxazolidinones
ES2705063T3 (es) 2001-08-15 2019-03-21 Pharmacia & Upjohn Co Llc Un cristal que comprende una sal de ácido L-málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida para su uso como un medicamento
CA2471144C (fr) * 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphes de 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate de sodium
JP2003261548A (ja) * 2002-03-07 2003-09-19 Teijin Ltd ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
DK1488790T3 (da) * 2002-03-28 2014-10-13 Teijin Pharma Ltd Fast præparat indeholdende en enkeltkrystalform A af etthiazolcarboxylsyrederivat
JP2008545627A (ja) * 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
JP5193863B2 (ja) * 2006-06-23 2013-05-08 帝人ファーマ株式会社 ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
CN101812035B (zh) * 2006-09-07 2012-03-21 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN101139325B (zh) * 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
JP2010509372A (ja) * 2006-11-13 2010-03-25 タケダ・フアーマシユーテイカルズ・ノース・アメリカ・インコーポレイテツド キサンチン酸化還元酵素阻害剤を使用する腎機能保持方法
CN102093308B (zh) * 2006-12-07 2012-08-29 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN1970547B (zh) * 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN102093309B (zh) * 2006-12-07 2012-07-04 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
BRPI0806608A2 (pt) * 2007-01-19 2011-09-06 Takeda Pharmaceuticals North America Inc métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios
CN101412700B (zh) * 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101386605B (zh) * 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
CN101759656B (zh) * 2008-12-12 2013-04-03 重庆医药工业研究院有限责任公司 非布司他新晶型及其制备方法
CN101768150B (zh) * 2009-01-05 2014-08-06 常州市第四制药厂有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CN101891702B (zh) * 2009-05-22 2012-07-04 重庆圣华曦药业股份有限公司 非布司他的晶体、制备方法及在药物中的应用
KR20120140267A (ko) 2009-06-10 2012-12-28 테바 파마슈티컬 인더스트리즈 리미티드 페북소스타트의 결정형
EP2455372B1 (fr) 2009-07-15 2017-10-11 Teijin Pharma Limited Procédé de fabrication de cristaux d'acide 2-(3-cyano-4-isobutyloxyphényl)-4-méthyl-5-thiazolecarboxylique polymorphique par une méthode d'addition d'un solvant médiocre
JP5519201B2 (ja) * 2009-07-15 2014-06-11 光孝 北村 ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
CN103936689B (zh) * 2009-07-17 2016-08-17 北京利乐生制药科技有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
WO2011080651A2 (fr) 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Formes polymorphes de fébuxostat
EP2536699A2 (fr) 2010-02-19 2012-12-26 Cadila Healthcare Limited Sels essentiellement purs de fébuxostat et leurs procédés de préparation
CA2792036A1 (fr) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphe d'acide 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylique
WO2011134101A1 (fr) * 2010-04-27 2011-11-03 上海凯米侬医药科技有限公司 Nouvelle forme cristalline n du fébuxostat et sa méthode de préparation
CN101824005B (zh) * 2010-04-27 2012-06-27 上海凯米侬医药科技有限公司 一种非布索坦的晶型q及其制备方法
EP2563768A4 (fr) * 2010-04-29 2013-07-31 Reddys Lab Ltd Dr Préparation of fébuxostat
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
ES2553584T3 (es) 2010-06-25 2015-12-10 Sandoz Ag Polimorfos de Febuxostat
TW201217347A (en) * 2010-07-13 2012-05-01 Interquim Sa Process for preparing the crystalline form a of febuxostat
WO2012020272A2 (fr) 2010-08-13 2012-02-16 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Nouveaux sels, polymorphes et solvates d'un ingrédient pharmaceutiquement actif
CN103298466B (zh) 2010-09-10 2015-11-25 武田制药美国有限公司 茶碱和非布索坦的联合治疗方法
WO2012038971A2 (fr) * 2010-09-24 2012-03-29 Hetero Research Foundation Nouveaux polymorphes de febuxostat
CN102442971B (zh) * 2010-10-13 2014-06-18 欣凯医药化工中间体（上海）有限公司 非布司他的晶型及其制备方法
WO2012048861A1 (fr) 2010-10-14 2012-04-19 Gador S.A. Nouvelle forme cristalline du febuxostat et son procédé de préparation
CA2814411A1 (fr) * 2010-10-28 2012-05-03 Mapi Pharma Limited Polymorphes de febuxostat
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
CN102127033A (zh) * 2011-01-21 2011-07-20 北京虹湾医药技术有限公司 非布索坦晶型及其工业化制备方法
EP2502920A1 (fr) 2011-03-25 2012-09-26 Sandoz Ag Procédé de cristallisation pour Febuxostat form A
WO2012131590A1 (fr) 2011-03-31 2012-10-04 Sandoz Ag Procédé de préparation amélioré du fébuxostat et de sa forme cristalline polymorphe c
CA2833101A1 (fr) 2011-04-15 2012-10-18 Poonam KAUSHIK Dispersion solide de febuxostat
WO2012153313A1 (fr) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Composition pharmaceutique de fébuxostat
WO2012168948A2 (fr) * 2011-06-06 2012-12-13 Hetero Research Foundation Procédé de préparation de fébuxostat
WO2012172461A1 (fr) 2011-06-13 2012-12-20 Ranbaxy Laboratories Limited Compositions pharmaceutiques de febuxostat
AU2012342011A1 (en) 2011-11-15 2014-06-05 Mylan Laboratories Ltd Process for the preparation of Febuxostat polymorphs
WO2013088449A1 (fr) 2011-12-16 2013-06-20 Natco Pharma Limited Forme cristalline stable de febuxostat et procédé de préparation correspondant
EP2925306A1 (fr) 2012-07-12 2015-10-07 Alembic Pharmaceuticals Limited Composition pharmaceutique de fébuxostat
EP2692342A1 (fr) 2012-07-30 2014-02-05 Interquim, S.A. Procédé pour la préparation de compositions pharmaceutiques comprenant du Febuxostat sous la forme de comprimés
WO2014057461A1 (fr) 2012-10-11 2014-04-17 Ranbaxy Laboratories Limited Procédé pour la préparation de forme cristalline g de fébuxostat
CN103936688A (zh) * 2013-01-21 2014-07-23 上海华拓医药科技发展股份有限公司 2-(3-氰基-4-(2-甲基丙氧基)苯基)-4-甲基-5-噻唑甲酸a晶的制备方法
KR20150138212A (ko) * 2013-03-29 2015-12-09 데이진 화-마 가부시키가이샤 피라졸 유도체
CN103396378B (zh) * 2013-07-29 2015-06-10 杭州朱养心药业有限公司 非布司他结晶
CN103588724B (zh) * 2013-09-10 2015-05-20 杭州华东医药集团新药研究院有限公司 一种非布司他晶型a及其制备方法
JP6283371B2 (ja) * 2013-10-22 2018-02-21 日本ケミファ株式会社 ２−［３−シアノ−４−（２−メチルプロポキシ）フェニル］−４−メチルチアゾール−５−カルボン酸の小型化結晶、その微粉化物及びこれらを含有する固形製剤
EP2881116A1 (fr) 2013-12-05 2015-06-10 Ranbaxy Laboratories Limited Composition de febuxostat
EP2902016A1 (fr) 2014-01-30 2015-08-05 Alfred E. Tiefenbacher (GmbH & Co. KG) Comprimé Febuxostat
CN103739568B (zh) * 2014-02-07 2015-09-16 浙江普洛康裕制药有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法
TR201902314T4 (tr) 2014-07-30 2019-03-21 Teijin Pharma Ltd Azol benzen türevi ve bunun kristali.
EP3002006A1 (fr) 2014-10-01 2016-04-06 Bluepharma - Industria Farmacêutica, S.A. Composition pharmaceutique capable de l'incorporation de febuxostat dans les modifications cristallines F10, II, G et A
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
WO2016171254A1 (fr) * 2015-04-22 2016-10-27 日本ケミファ株式会社 Cristaux d'acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique, procédé de fabrication de ceux-ci, et utilisation de ceux-ci
EP3153158A1 (fr) 2015-10-09 2017-04-12 Stada Arzneimittel Ag Pastille orale de febuxostat
CN107540630A (zh) * 2016-06-29 2018-01-05 康普药业股份有限公司 一种非布司他化合物及制备方法
GR1009119B (el) 2016-06-30 2017-09-18 "Φαρματεν Α.Β.Ε.Ε." Φαρμακευτικο σκευασμα περιεχον ενα μη πουρινικο επιλεκτικο αναστολεα της οξειδασης της ξανθινης και μεθοδος παρασκευης αυτου
KR20180013563A (ko) * 2016-07-29 2018-02-07 한미정밀화학주식회사 고순도 결정형 페북소스타트의 개선된 제조 방법
CN106565627B (zh) * 2016-10-10 2020-01-10 扬子江药业集团有限公司 一种非布司他药用晶型的制备方法
GR1009659B (el) 2018-09-07 2019-11-28 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα συμπλοκο αλατος της φεβουξοστατης με οξειδιο του μαγνησιου και μεθοδος για την παρασκευη αυτου
JP7389044B2 (ja) 2018-09-28 2023-11-29 株式会社カネカ 安定性に優れた還元型補酵素ｑ１０結晶の製造方法
CN112390766B (zh) * 2019-08-13 2022-09-06 浙江天宇药业股份有限公司 一种非布司他a晶型的制备方法
CN111004191A (zh) * 2019-10-24 2020-04-14 武汉光谷亚太医药研究院有限公司 一种大粒径非布司他a晶的制备方法
JP7506475B2 (ja) * 2019-12-26 2024-06-26 東和薬品株式会社 フェブキソスタット製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8506572D0 (en) † 1985-03-14 1985-04-17 Appointrose Ltd Fire-resistant enclosures
EP0237608B1 (fr) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO La forme sigma cristalline, anhydre de 2-[4-(2-furoyl-(2-pipérazin)-1-yl]-4-amino-6,7-diméthoxyquinazoline hydrochlorure et procédé pour sa préparation
SU1417437A1 (ru) * 1986-12-30 1994-01-30 Институт органической и физической химии им.А.Е.Арбузова Способ получения 4-тиазолкарбоновой кислоты
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
DE69122084T2 (de) * 1990-11-30 1997-04-03 Teijin Ltd., Osaka 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
JP2706037B2 (ja) * 1993-04-13 1998-01-28 帝人株式会社 シアノ化合物およびその製造方法
JP3202607B2 (ja) * 1996-08-01 2001-08-27 帝人株式会社 ２−（４−アルコキシ−３−シアノフェニル）チアゾール誘導体の製造法
AU748026B2 (en) 1998-06-19 2002-05-30 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)- 4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
DK1488790T3 (da) 2002-03-28 2014-10-13 Teijin Pharma Ltd Fast præparat indeholdende en enkeltkrystalform A af etthiazolcarboxylsyrederivat

Also Published As

Publication number Publication date
DK1956015T4 (en) 2019-02-11
IL134594A0 (en) 2001-04-30
JP3547707B2 (ja) 2004-07-28
AU4289299A (en) 2000-01-05
CY2010006I1 (el) 2012-01-25
NZ503326A (en) 2002-02-01
RU2198169C2 (ru) 2003-02-10
RU2198169C3 (ru) 2017-07-20
CY1109720T1 (el) 2012-01-25
PT1020454E (pt) 2009-12-21
EP1020454B1 (fr) 2009-11-25
HK1029788A1 (en) 2001-04-12
PL200710B1 (pl) 2009-01-30
US6225474B1 (en) 2001-05-01
HRP20000092A2 (en) 2000-08-31
PT1956015E (pt) 2011-11-02
CY2010006I2 (el) 2012-01-25
DK1956014T3 (en) 2019-04-15
ATE522512T2 (de) 2011-09-15
EP1956015A3 (fr) 2008-09-17
SK287928B6 (sk) 2012-04-03
EP1956014A3 (fr) 2008-08-20
ES2718467T3 (es) 2019-07-02
SK2202000A3 (en) 2000-11-07
IS9022A (is) 2013-01-25
CA2301863C (fr) 2009-01-27
NO321308B1 (no) 2006-04-24
EP1956015A2 (fr) 2008-08-13
HUP0004325A2 (hu) 2001-10-28
SI1956015T1 (sl) 2011-10-28
EP1956014A2 (fr) 2008-08-13
NO20000789L (no) 2000-02-17
FR10C0022I1 (fr) 2010-05-14
CN102020617A (zh) 2011-04-20
CY1111841T1 (el) 2015-10-07
TR200000458T1 (tr) 2000-10-23
ES2371786T5 (es) 2019-04-22
WO1999065885A1 (fr) 1999-12-23
DK1956015T3 (da) 2011-09-26
EP1956015B2 (fr) 2018-11-14
CA2566652A1 (fr) 1999-12-23
IN191537B (fr) 2003-12-06
EP1020454B2 (fr) 2013-01-23
EP1956015B1 (fr) 2011-08-31
CA2566652C (fr) 2008-10-21
ES2336287T3 (es) 2010-04-09
CN102659712A (zh) 2012-09-12
IS2886B (is) 2014-07-15
ZA200000737B (en) 2000-09-08
IS9021A (is) 2013-01-25
SK287946B6 (sk) 2012-06-04
IS3002B (is) 2018-09-15
DE69941672D1 (de) 2010-01-07
NO20000789D0 (no) 2000-02-17
ATE449765T1 (de) 2009-12-15
EP1956014B1 (fr) 2019-01-16
UA57611C2 (uk) 2003-06-16
CZ2000582A3 (cs) 2000-07-12
HRP20120217A2 (hr) 2012-05-31
BG104159A (en) 2000-08-31
GT199900216A (es) 2001-06-08
PL338780A1 (en) 2000-11-20
BG64734B1 (bg) 2006-01-31
KR100511183B1 (ko) 2005-08-30
IS9020A (is) 2013-01-25
ES2371786T3 (es) 2012-01-10
BE2010C024I2 (en) 2018-08-24
IL134594A (en) 2004-12-15
ES2336287T5 (es) 2013-04-02
PT1956014T (pt) 2019-04-24
SI1020454T2 (sl) 2013-03-29
HUP0004325A3 (en) 2001-12-28
EP2404910A2 (fr) 2012-01-11
CN1275126A (zh) 2000-11-29
HRPK20000092B1 (hr) 2001-10-31
HU229405B1 (en) 2013-12-30
SI1956014T1 (sl) 2019-02-28
SI1956015T2 (sl) 2018-12-31
ID25775A (id) 2000-11-02
CZ298170B6 (cs) 2007-07-11
IS5377A (is) 2000-02-17
DK1020454T3 (da) 2010-01-04
SI1020454T1 (sl) 2010-02-26
DE122010000013I1 (de) 2010-07-08
FR10C0022I2 (fr) 2013-08-16
LT1956014T (lt) 2019-03-25
CA2301863A1 (fr) 1999-12-23
HRP20000092C1 (en) 2012-04-30
HK1118293A1 (en) 2009-02-06
TWI248439B (en) 2006-02-01
EP1020454A1 (fr) 2000-07-19
HU230799B1 (hu) 2018-06-28
CN102020617B (zh) 2019-04-23
KR20010023061A (ko) 2001-03-26
EP2404910A3 (fr) 2014-10-29
DK1020454T4 (da) 2013-11-25
BR9906539A (pt) 2000-08-15
HRP20120217B1 (hr) 2019-04-05
EP1020454A4 (fr) 2002-05-15
AU748026B2 (en) 2002-05-30
LU91682I9 (fr) 2019-01-09

Similar Documents

Publication Publication Date Title
LU91682I2 (fr) Adenuric - febuxostat
MY115512A (en) Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
ECSP993280A (es) Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos
DK0924195T3 (da) Fremgangsmåde til fremstilling af aminocyanacetamid
UY25863A1 (es) Polimorfos de acido 2-(3-ciano-4-isobutiloxi fenil)4-metil 5 - tiazol carboxilico y metodo de produccion de los mismos.
AR021668A1 (es) Polimorfos de acido 2-(3-ciano-4-isobutiloxi fenil)-4-metil-5-tiazol carboxilico y metodo de produccion de los mismos